Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Nov;64(5):899–902. doi: 10.1038/bjc.1991.422

Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.

S Kawa 1, H Oguchi 1, T Kobayashi 1, M Tokoo 1, S Furuta 1, M Kanai 1, T Homma 1
PMCID: PMC1977472  PMID: 1931612

Abstract

CA19-9, a serum marker for pancreatic cancer, gives false-negative results in patients who are negative for the Lewis blood group phenotype. To determine whether other markers may compensate for this drawback, serum levels of CA50, Span-1, sialyl SSEA-1 and Dupan-2 were assayed and compared with those of CA19-9 in 207 normal subjects and in 200 patients with pancreatic carcinoma whose Lewis blood group phenotypes were confirmed. In normal subjects with the Lewis negative phenotype, the serum levels of CA50 and Span-1, as well as CA19-9, were significantly low, whereas those of sialyl SSEA-1 were independent of the Lewis blood group phenotype. Serum levels of Dupan-2 were significantly higher in normal subjects with the Le (a-b-) phenotype as compared with those with Le(a-b+). The sensitivity for pancreatic carcinoma was 81% for CA19-9, 84% for CA50, 82% for Span-1, 51% for sialyl SSEA-1 and 63% for Dupan-2. Among the 39 CA19-9 negative patients, 13 were determined as being Lewis negative by the serum dot-ELISA technique. Although the positive rates were essentially comparable when each marker was combined with CA19-9, a highly elevated serum level of Dupan-2, which strongly suggested the presence of malignancy, was most frequently encountered in 39 patients who were not diagnosed by CA19-9 assay, especially those with Lewis negative blood groups. With regard to the three other markers, we found few patients with a highly elevated serum level in either the Lewis-negative or -positive groups. We conclude that Dupan-2 tended to be elevated in patients with pancreatic cancer who were negative for the Lewis blood group phenotype.

Full text

PDF
899

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chung Y. S., Ho J. J., Kim Y. S., Tanaka H., Nakata B., Hiura A., Motoyoshi H., Satake K., Umeyama K. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer. 1987 Oct 1;60(7):1636–1643. doi: 10.1002/1097-0142(19871001)60:7<1636::aid-cncr2820600736>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  2. Cooper E. H., Forbes M. A., Taylor M. An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease. Br J Cancer. 1990 Dec;62(6):1004–1005. doi: 10.1038/bjc.1990.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Del Villano B. C., Brennan S., Brock P., Bucher C., Liu V., McClure M., Rake B., Space S., Westrick B., Schoemaker H. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983 Mar;29(3):549–552. [PubMed] [Google Scholar]
  4. Fukushi Y., Nudelman E., Levery S. B., Hakomori S., Rauvala H. Novel fucolipids accumulating in human adenocarcinoma. III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3NeuAcV3III3Fuc2nLc6). J Biol Chem. 1984 Aug 25;259(16):10511–10517. [PubMed] [Google Scholar]
  5. Hansson G. C., Zopf D. Biosynthesis of the cancer-associated sialyl-Lea antigen. J Biol Chem. 1985 Aug 5;260(16):9388–9392. [PubMed] [Google Scholar]
  6. Hawkes R., Niday E., Gordon J. A dot-immunobinding assay for monoclonal and other antibodies. Anal Biochem. 1982 Jan 1;119(1):142–147. doi: 10.1016/0003-2697(82)90677-7. [DOI] [PubMed] [Google Scholar]
  7. Hirano K., Kawa S., Oguchi H., Kobayashi T., Yonekura H., Ogata H., Homma T. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels. J Natl Cancer Inst. 1987 Dec;79(6):1261–1268. [PubMed] [Google Scholar]
  8. Holmgren J., Lindholm L., Persson B., Lagergård T., Nilsson O., Svennerholm L., Rudenstam C. M., Unsgaard B., Yngvason F., Pettersson S. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J (Clin Res Ed) 1984 May 19;288(6429):1479–1482. doi: 10.1136/bmj.288.6429.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kannagi R., Fukushi Y., Tachikawa T., Noda A., Shin S., Shigeta K., Hiraiwa N., Fukuda Y., Inamoto T., Hakomori S. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine. Cancer Res. 1986 May;46(5):2619–2626. [PubMed] [Google Scholar]
  10. Kiriyama S., Hayakawa T., Kondo T., Shibata T., Kitagawa M., Ono H., Sakai Y. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer. 1990 Apr 1;65(7):1557–1561. doi: 10.1002/1097-0142(19900401)65:7<1557::aid-cncr2820650718>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  11. Kobayashi T., Kawa S., Tokoo M., Oguchi H., Kiyosawa K., Furuta S., Kanai M., Homma T. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer. Scand J Gastroenterol. 1991 Jul;26(7):787–797. doi: 10.3109/00365529108998600. [DOI] [PubMed] [Google Scholar]
  12. Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 Nov;5(6):957–971. doi: 10.1007/BF01542654. [DOI] [PubMed] [Google Scholar]
  13. Lan M. S., Batra S. K., Qi W. N., Metzgar R. S., Hollingsworth M. A. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem. 1990 Sep 5;265(25):15294–15299. [PubMed] [Google Scholar]
  14. Lan M. S., Finn O. J., Fernsten P. D., Metzgar R. S. Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. Cancer Res. 1985 Jan;45(1):305–310. [PubMed] [Google Scholar]
  15. Lindholm L., Holmgren J., Svennerholm L., Fredman P., Nilsson O., Persson B., Myrvold H., Lagergård T. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol. 1983;71(2):178–181. doi: 10.1159/000233384. [DOI] [PubMed] [Google Scholar]
  16. Masson P., Pålsson B., Andrén-Sandberg A. Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br J Cancer. 1990 Jul;62(1):118–121. doi: 10.1038/bjc.1990.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Metzgar R. S., Gaillard M. T., Levine S. J., Tuck F. L., Bossen E. H., Borowitz M. J. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res. 1982 Feb;42(2):601–608. [PubMed] [Google Scholar]
  18. Metzgar R. S., Rodriguez N., Finn O. J., Lan M. S., Daasch V. N., Fernsten P. D., Meyers W. C., Sindelar W. F., Sandler R. S., Seigler H. F. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci U S A. 1984 Aug;81(16):5242–5246. doi: 10.1073/pnas.81.16.5242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Månsson J. E., Fredman P., Nilsson O., Lindholm L., Holmgren J., Svennerholm L. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta. 1985 Mar 27;834(1):110–117. doi: 10.1016/0005-2760(85)90182-1. [DOI] [PubMed] [Google Scholar]
  20. Pour P. M., Tempero M. M., Takasaki H., Uchida E., Takiyama Y., Burnett D. A., Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 1;48(19):5422–5426. [PubMed] [Google Scholar]
  21. Sawabu N., Toya D., Takemori Y., Hattori N., Fukui M. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers. Int J Cancer. 1986 May 15;37(5):693–696. doi: 10.1002/ijc.2910370509. [DOI] [PubMed] [Google Scholar]
  22. Stigendal L., Olsson R., Rydberg L., Samuelsson B. E. Blood group lewis phenotype on erythrocytes and in saliva in alcoholic pancreatitis and chronic liver disease. J Clin Pathol. 1984 Jul;37(7):778–782. doi: 10.1136/jcp.37.7.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]
  24. Yazawa S., Asao T., Izawa H., Miyamoto Y., Matta K. L. The presence of CA19-9 in serum and saliva from Lewis blood-group negative cancer patients. Jpn J Cancer Res. 1988 Apr;79(4):538–543. doi: 10.1111/j.1349-7006.1988.tb01624.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES